BiO2 Medical catches $12m to market emboli filter
This article was originally published in Clinica
BiO2 Medical has raised $12 million in Series C funding which will enable the San Antonio, Texas firm to commercialise its Angel pulmonary embolism prevention device. The round was led by new investor Remeditex Ventures, with participation from BiO2's existing investors.
You may also be interested in...
Minimally invasive glaucoma surgery specialist Glaukos saw its stock leap 40% in the wake of a worldwide recall by much bigger rival Alcon of its CyPass microstent.
Roland Diggelmann will end his decade-long career at Roche Diagnostics at the end of September. The business's head of EMEA Michael Heuer will take Diggelmann's place while the search is on for his replacement.
Philips has added a new pulse oximetry platform to its patient monitoring portfolio, with the acquisition of Xhale Assurance.